Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time. Click here to view full Press release
Enhancing the potential of methotrexate. Optimise rheumatism treatment in Finland with Metoject® PEN1 and ensure long-term success of therapy Helsinki / Wedel (September 21, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the FIN-ERA cohort suggest that Finnish rheumatology exploits the […]
Methotrexate for psoriasis: effective, safe, favourable. Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva. Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no […]
Enhancing the potential of methotrexate. Optimise rheumatism treatment with Metoject® and ensure long-term success of therapy Stuttgart / Wedel (September 11, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the CAPEA cohort suggest that German rheumatology exploits the potential of methotrexate […]
Update on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended British Association of Dermatologists’ guidelines reaffirms https://www.cialispascherfr24.com/ the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis Recently in The Lancet published METOP trial meets the need […]
/wp-content/uploads/2017/03/logoBlueNew3.png00Admin medac/wp-content/uploads/2017/03/logoBlueNew3.pngAdmin medac2017-07-07 15:08:222018-10-11 15:05:53Press Release - medac at the BAD meeting 2017
Tämä sivusto käyttää evästeitä. Jatkaaksesi sivustomme käyttöä, sinun tulee hyväksyä evästeet.
Press release – First marketing authorisation worldwide for methotrexate in moderate psoriasis
/in kategorioimaton /by Admin medacMedac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time. Click here to view full Press release
Press release – Medac Finland – 10-years anniversary symposium
/in kategorioimaton /by Admin medacEnhancing the potential of methotrexate. Optimise rheumatism treatment in Finland with Metoject® PEN1 and ensure long-term success of therapy Helsinki / Wedel (September 21, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the FIN-ERA cohort suggest that Finnish rheumatology exploits the […]
Press release – Medac at the EADV 2017
/in kategorioimaton /by Admin medacMethotrexate for psoriasis: effective, safe, favourable. Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva. Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no […]
Press release – Medac at DGRh 2017
/in kategorioimaton /by Admin medacEnhancing the potential of methotrexate. Optimise rheumatism treatment with Metoject® and ensure long-term success of therapy Stuttgart / Wedel (September 11, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the CAPEA cohort suggest that German rheumatology exploits the potential of methotrexate […]
Press Release – medac at the BAD meeting 2017
/in kategorioimaton /by Admin medacUpdate on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended British Association of Dermatologists’ guidelines reaffirms https://www.cialispascherfr24.com/ the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis Recently in The Lancet published METOP trial meets the need […]